Condition
Sarcomatoid Mesothelioma
Total Trials
3
Recruiting
0
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
2 of 0 completed with results
Key Signals
2 with results0
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Active Not Recruiting2
Terminated1
Clinical Trials (3)
Showing 3 of 3 trials
NCT01064648Phase 1Active Not Recruiting
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
NCT02399371Phase 2Active Not Recruiting
Pembrolizumab in Treating Patients With Malignant Mesothelioma
NCT01861301Phase 2Terminated
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
Showing all 3 trials